Abstract: Patients on levodopa therapy frequently require additional antipsychotic pharmacotherapy. However, consideration must be given to antagonistic interactions on dopamine receptors between levodopa and antipsychotics, and efficacy and safety of such combinations. We therefore aimed to explore the practice and rationale of coprescription between levodopa and antipsychotics in psychiatric patients.A descriptive retrospective study based on cross-sectional prescription data repeatedly collected from psychiatric inpatients through the international Drug Safety in Psychiatry (AMSP) program between 1994 and 2008 was undertaken.Within a population of 84 596 psychiatric patients the prevalence of levodopa therapy was 1.0% (n=886). Among those patients on levodopa therapy 59.6% (n=528) also received antipsychotics. Quetiapine coprescription increased after its first marketing in 2000 to 45.9% in 2008. Coprescription of clozapine and olanzapine decreased from up to 25 and 22%, respectively, before to less than 10% after the introduction of quetiapine. Coprescribing of other antipsychotics remained approximately stable with average prevalences between 6 and less than 1%.Quetiapine has now replaced clozapine as the most frequently coprescribed neuroleptic in psychiatric patients with levodopa therapy. This is in accordance with recent data indicating a low potential for clinically relevant interactions with levodopa and efficacy against psychosis in levodopa-treated patients. The combined use of antipsychotics other than quetiapine and clozapine with levodopa is less common and generally not supported by appropriate evidence. 
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ABSTRACT
Introduction Patients with levodopa therapy frequently require additional antipsychotic pharmacotherapy. However, consideration must be given to antagonistic interactions on dopamine receptors between levodopa and antipsychotics, and efficacy and safety of such combinations. We therefore aimed to explore the practice and rationale of coprescription between levodopa and antipsychotics in psychiatric patients.
Methods
Descriptive retrospective study based on cross-sectional prescription data repeatedly collected from psychiatric inpatients through the international Drug Safety in Psychiatry (AMSP) program between 1994 and 2008.
Results Within a population of 84,596 psychiatric patients the prevalence of levodopa therapy was 1.0% (n=886). Among those patients with levodopa therapy 59.6% (n=528) also received antipsychotics. Quetiapine coprescription increased after its first marketing in 2000 to 45.9% in 2008. Coprescription of clozapine and olanzapine decreased from up to 25 and 22%, respectively, before to less than 10% after introduction of quetiapine. Coprescribing of other antipsychotics remained approximately stable with average prevalences between 6 and less than 1%.
Discussion Quetiapine has now replaced clozapine as the most frequently coprescribed neuroleptic in psychiatric patients with levodopa therapy. This is in accordance with recent data indicating a low potential for clincially relevant interactions with levodopa and efficacy against psychosis in levodopa-treated patients.
The combined use of other antipsychotics than quetiapine and clozapine with levodopa is less common and generally not supported by appropriate evidence.
INTRODUCTION
Levodopa is indicated for the treatment of idiopathic Parkinson's disease (PD),
Parkinson syndromes, and restless legs syndrome (RLS), but not for drug-induced extrapyramidal symptoms (EPS). PD is associated with psychosis with an estimated incidence rate of 79.7 per 1000 person-years [1] , and central dopaminergic overactivity as well as an imbalance in the cholinergic neurotransmission play a key role in the underlying pathophysiology [2, 3] . On the one hand PD itself is associated with psychosis [4] . But more importantly, in the majority of PD patients psychosis is actually precipitated by dopaminergic treatment for PD, including levodopa [1, 5, 6] .
Similarly, the dopamine system is also involved in the pathophysiology of RLS [7] , which is the foundation for its treatment with dopaminergic drugs including levodopa.
In analogy to PD dopaminergic treatment for RLS is also associated with psychotic disorders [8] . Therefore, in order to control psychotic symptoms in levodopa-treated patients neurologists and psychiatrists frequently combine levodopa with antipsychotics in clinical practice.
In a previous study we investigated the prevalences of interacting drug combinations in a large population of psychiatric inpatients collected through the international Drug Safety in Psychiatry (AMSP) program, but our analyses did not yet include detailed studies of drug interactions between selected drug classes of interest [9] . The current study aimed to explore the combined use of levodopa and antipsychotics in a large representative psychiatric inpatient population that reflects prescribing behavior in clinical practice over time.
METHODS
Data Source
AMSP is an ongoing international multicenter drug safety program that has been collecting data on pharmacotherapy and adverse drug events from psychiatric hospitals in a naturalistic setting since 1993. Its methods have been described in detail elsewhere [10, 11] . Briefly, AMSP consists of two principle data collections from more than 80 hospitals in Germany, Switzerland and Austria, and more recently also from one hospital each in Belgium and Hungary. First, in a cross-sectional approach all participating hospitals survey psychiatric inpatients on two reference days per year.
All drugs administered on these days are recorded along with the patients' age, gender and leading psychiatric diagnoses. Second, severe adverse drug events that occur at these hospitals during psychopharmacological drug treatment are continuously reported and collected. For the current study we used only the cross-sectional AMSP prescription dataset.
Study population and design
Selection of the study population and data management have been described in detail in our previous study [9] . Briefly, we received an anonymized dataset that had been extracted from the AMSP database and contained all cross-sectional data collected from the AMSP program between 1994 and 2008. Subsequently we executed extensive reformatting, quality controls and matching of ATC codes to all prescribed active substances. Compared to our previous study another 11 patients were excluded for the current analysis because the date of data collection was not specified, and this would have interfered with time trend analyses. Within the resulting population of 84,567 patients we identified all patients with prescriptions for levodopa and recorded 6 all concomitant prescriptions at the day of prescription data collection. The ethics committee of the Ludwig Maximilian University Munich, the location of the AMSP main data center, had approved the study with a waiver of authorization.
Data analysis
Data analysis was primarily descriptive with presentation of results in tables and graphs as appropriate. The chi-square test was used for comparing changes in the proportion of patients with prescriptions of specific drugs over two different time strata. Alternatively, we fitted changes over several calendar years to a simple linear regression model. Data management, analyses, tables and graphs were done using STATA Version 11.2 for MacOS X (STATA Corporation, College Station, TX, USA) and SPSS Version 18 for MacOS X (IBM Corporation, Somers, NY, USA).
RESULTS
Characteristics and overall pharmacotherapy of patients with levodopa therapy
Among 84,567 psychiatric inpatients we identified 886 patients with a prescription of levodopa. Looking at time trends for levodopa use in the source population we found that the proportion of patients with levodopa prescriptions increased by 29% from 
Coprescribing of levodopa and antipsychotics
Combined use of levodopa and antipsychotics is presented in Table 4 and with an average prevalence between 0.1 and 5.9% (see Table 4 ). Furthermore, we also identified seven patients where levodopa was combined with the formally contraindicated antidopaminergic drug metoclopramide. 
DISCUSSION
